Novel agents are increasingly used during induction therapy for multiple myeloma (MM), but there is concern about their potential impact on stem cell mobilization. Regimens containing either thalidomide or cyclophosphamide have little or no impact on stem cell collection. In this retrospective review of 136 patients with newly diagnosed MM, we show that the combination of thalidomide and oral CY with dexamethasone (CTD) during induction therapy impaired stem cell mobilization substantially. Compared with VAD (vincristine, doxorubicin, dexamethasone) and a VAD-like induction regimen, the stem cell collection yield after CTD was decreased by 49% (median 5.0 vs 9.8 Â 10 6 CD34 þ cells/kg, Po0.001). Following CTD, more patients failed to mobilize enough stem cells for one (25.4 vs 5.8%, P ¼ 0.002) or two (39.4 vs 15.9%, P ¼ 0.002) transplants. These results demonstrate that the combination of thalidomide and oral CY impairs stem cell mobilization and indicate that drugs with no previously reported relevant effect on stem cell mobilization can have a substantial impact when given in combination.
Introduction
High-dose chemotherapy and auto-SCT forms the backbone of treatment for a large proportion of patients with multiple myeloma (MM). Several trials have demonstrated that patients who undergo auto-SCT have a superior PFS when compared with conventional therapy, and some of these studies have shown improved OS. 1 One randomized trial comparing single vs tandem auto-SCT demonstrated a survival advantage for tandem transplants in those patients who failed to achieve at least a very good partial response after the first transplant. 2 Furthermore, auto-SCT is widely used in the treatment of relapsed myeloma. Thus, the collection of a sufficient number of autologous haematopoietic stem cells (HSCs) for one or more courses of highdose chemotherapy is a key step in providing optimal treatment for many MM patients.
Traditionally, stem cells have been collected after several courses of induction therapy for myeloma. Until recently, the most commonly used regimens consisted of dexamethasone alone, VAD (vincristine, doxorubicin, dexamethasone) or VAD-like combinations, which rarely result in stem cell mobilization failure. The alkylating agent melphalan has been avoided in induction therapies because it hampers stem cell collection. 3 In recent years, the novel agents thalidomide, lenalidomide and bortezomib have been investigated as first-line treatment and are likely to become integral parts of induction therapy. 4 However, there is concern about their safety regarding the ability to collect sufficient numbers of stem cells, which is reflected in a recently published consensus perspective of the International Myeloma Working Group (IMWG). 5 Several studies have indicated that lenalidomide substantially decreases the number of HSCs collected. [6] [7] [8] In contrast, the upfront use of thalidomide causes no or only a minor reduction in the stem cell yield, and no study has reported an increased rate of mobilization failure after induction therapies containing thalidomide. [9] [10] [11] [12] Several new induction regimens combine novel agents with CY. Although CY is an alkylating drug-like melphalan, it has little or no impact on stem cell mobilization when given during induction therapy. 5, [13] [14] [15] We considered the possibility that drugs that have not previously been found to impair stem cell collection could cause an unexpectedly high rate of mobilization failure when given together. In this study, we report that the combination of oral CY and thalidomide with dexamethasone (CTD) reduces the stem cell collection yield and results in stem cell mobilization failure in a substantial proportion of patients.
Patients and methods
We carried out a retrospective analysis of the outcome of PBSC mobilizations at our institution in 136 consecutive MM patients. Patients who had received induction therapy with CTD (n ¼ 67) were compared with a control group of patients (n ¼ 69) who had received VAD (n ¼ 41) or Z-Dex (oral idarubicin and dexamethasone; n ¼ 28) during the same period. The CTD regimen consisted of oral CY (500 mg on days 1, 8 and 15 (and day 22, if treated on a 28-day cycle)), thalidomide (100 mg daily for 3 weeks, then up to 200 mg daily) and dexamethasone (40 mg daily on days 1-4 and 12-15 (or [15] [16] [17] [18] , repeated every 21 (or 28) days). The VAD and Z-Dex regimens have been described previously. 16 Patients who had received multiple previous therapies or thalidomide maintenance between the end of induction therapy and stem cell mobilization were not included. All mobilizations were performed with CY (2-4 g/m 2 ) and G-CSF from day 5 after CY until stem cell collection was completed. Apheresis was attempted from day 13, if the peripheral blood CD34 þ cell count was 410 Â 10 3 /mL, and discontinued when our standard collection target of X4 Â 10 6 CD34 þ cells/kg was reached. In patients failing to achieve the standard target, a minimal target of X2 Â 10 6 CD34 þ cells/kg to undergo one auto-SCT was accepted. These targets were valid for all patients included in the study, and no changes were made to the mobilization and apheresis procedures throughout the study period. Groups were compared using Mann-Whitney test for continuous data and w 2 -test for categorical data. P-values o0.05 were deemed to be statistically significant. Table 1 shows baseline demographics of both groups. More patients in the CTD group had Durie/Salmon stage III at diagnosis, but patients in the CTD and control groups did not differ with regard to gender distribution, age and remission status at the time of mobilization. The median number of induction therapy cycles was higher in the CTD group compared with the control group.
Results
The total number of CD34 þ HSCs collected was substantially lower in the CTD group (median 5.0 Â 10 6 /kg, range 0.0-42.6) compared with the control group (median 9.8 Â 10 6 /kg, range 0.0-66.8; Po0.001; Figure 1a ). The number of HSCs harvested on the first day of apheresis was also significantly lower in the CTD group (median 2.7 vs 7.0 Â 10 6 /kg, range 0-42.6 vs 0.0-66.8; Po0.001; Figure 1a) , as was the number of stem cells collected per apheresis procedure (median 2.5 vs 6.5 Â 10 6 /kg, range 0-42.6 vs 0.0-66.8; Po0.001; Figure 1a) . Compared with the control group, more patients in the CTD group underwent X2 apheresis procedures (54.4 vs 35.8%, P ¼ 0.038; Figure 1b ). There was no significant difference between the VAD and Z-Dex groups in terms of total stem cell yield, number of apheresis procedures and the number of patients achieving the standard or minimal stem cell collection yield (data not shown).
In the CTD group, 39.4% of the patients failed to achieve the standard collection target of X4 Â 10 6 CD34 þ cells/kg, which was significantly higher than in the control group (15.9%, P ¼ 0.002; Figure 2 ). Importantly, one in four patients (n ¼ 17, 25.4%) in the CTD group did not reach the minimal stem cell collection target of X2 Â 10 6 CD34 þ cells/kg, whereas only a few patients in the control group failed to achieve the minimal target (n ¼ 4, 5.8%, P ¼ 0.002; Figure 2 ). The failure rate on the first day of apheresis was also higher in the CTD group compared with the control group for both the standard (59.7 vs 31.9%, P ¼ 0.001; Figure 2 ) and the minimal target (38.8 vs 17.4%, P ¼ 0.005; Figure 2) .
In patients who do not mobilize adequate numbers of stem cells after induction therapy with lenalidomide, a higher number of treatment cycles and older age were shown to be the most important predictors of collection failure. 6, 17 However, age and number of induction therapy cycles did not have an impact on mobilization failure or stem cell collection yield in univariate analysis in the entire cohort or the CTD group alone in our study (data not shown). The HSC collection yield in patients who had received 2-4 cycles of CTD (n ¼ 18; median 5.04 Â 10 ) and G-CSF (n ¼ 11), or plerixafor (240 mg/kg) and G-CSF (n ¼ 3). One patient who had received etoposide died from pneumonia before stem cell collection, in the others stem cell apheresis was performed at a median of 48 (range, 23-90) days after the first failed attempt and resulted in the collection of 4.5 Â 10 6 CD34 þ cells/kg (median, range 1.8-12).
Discussion
A number of studies have demonstrated that the use of either CY or thalidomide during induction therapy for MM has little or no impact on stem cell mobilization. The Nordic Myeloma Study Group found no difference in the stem cell collection yield between patients who had received CY and dexamethasone compared with those who had received VAD, and stem cell mobilization was successful in 97% of patients in both groups. 15 In another study, all patients who received oral CY with dexamethasone and bortezomib for induction therapy subsequently had enough stem cells collected for one transplant, with a median harvest yield of 411 Â 10 6 CD34 þ cells/kg. 13 Although the number of patients in the latter study was small, the observations indicate that CY does not have a substantial impact on stem cell mobilization. Patients who received thalidomide in combination with doxorubicin and dexamethasone (TAD) in a Dutch-Belgian and German study had a median collection yield of 7.4 and 9.8 Â 10 6 CD34 þ cells/kg, respectively. This was significantly lower than in patients who had received induction therapy with VAD (by approximately 10% in the German arm and 20% in the Dutch-Belgian arm). However, mobilization failure rates after TAD were low (3 and 4%) and not different from VAD (4 and 7%). 11 In a study comparing thalidomide plus dexamethasone with dexamethasone alone for induction therapy, no difference in mobilization failures was observed (10% in both arms). 10 In another study comparing thalidomide plus dexamethasone with VAD as primary therapy, there was no significant difference between the number of HCSs collected or the proportion of patients mobilizing enough stem HSCs for two transplants. 9 Taken together, these reports suggest that thalidomide may have a minor impact on stem cell mobilization but does not cause an increased rate of mobilization failures. Our findings in the group of patients who had received VAD/Z-Dex are similar to those reported in the literature for VAD and VAD-like regimens or dexamethasone only. By comparison, the number of stem cells collected in patients who had been treated with the CTD combination was reduced by 49%. Moreover, the number of patients who failed to achieve the minimal collection target was increased more than fourfold to over 25%. These results demonstrate that the combination of thalidomide and oral CY impairs stem cell mobilization substantially and results in a high rate of mobilization failures. Given that neither thalidomide nor CY have been reported to have more than a minor effect on stem cell mobilization, the results of this study also suggest that the impact of CTD on stem cell mobilization is due to the combination of the two drugs. However, it cannot be concluded if thalidomide or oral CY has a greater effect, nor is it possible to speculate if i.v. CY would have the same impact.
HSCs are mobilized into the blood when chemokines and chemokine receptors, whose normal interaction retains stem cells in the BM, are cleaved by proteases that are released from myeloid cells in the BM after administration of G-CSF or chemotherapy. 18 It has been suggested that lenalidomide causes mobilization failure by upregulating the secretion of G-CSF by myeloid cells in the marrow and subsequent tachyphylactic responses when mobilizing chemotherapy and/or G-CSF are administered. 5 It is conceivable that the combination of thalidomide and oral CY has an additive effect on the BM microenvironment that renders HSCs 'resistant' to mobilizing agents by a similar mechanism. Although stem cell mobilization with CY plus G-CSF is generally considered to be highly effective and can overcome mobilization failures associated with previous lenalidomide treatment, 17 our results indicate the possibility that alternative mobilization regimens including etoposide or Plerixafor may be more suitable in patients who have received CTD induction therapy.
In the era of novel therapeutic drugs, the number of auto-SCTs for treatment of MM that are reported to the international registries continues to increase. [19] [20] The results of this study highlight the need to carefully assess new drug combinations for their potential impact on stem cell mobilization.
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